[go: up one dir, main page]

WO2003014309A3 - Recepteurs de l'interleukine-1 dans le traitement de maladies - Google Patents

Recepteurs de l'interleukine-1 dans le traitement de maladies Download PDF

Info

Publication number
WO2003014309A3
WO2003014309A3 PCT/US2002/024948 US0224948W WO03014309A3 WO 2003014309 A3 WO2003014309 A3 WO 2003014309A3 US 0224948 W US0224948 W US 0224948W WO 03014309 A3 WO03014309 A3 WO 03014309A3
Authority
WO
WIPO (PCT)
Prior art keywords
interleukin
receptors
diseases
treatment
1racp
Prior art date
Application number
PCT/US2002/024948
Other languages
English (en)
Other versions
WO2003014309A2 (fr
Inventor
John E Sims
Dirk E Smith
Original Assignee
Immunex Corp
John E Sims
Dirk E Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp, John E Sims, Dirk E Smith filed Critical Immunex Corp
Priority to EP02759279A priority Critical patent/EP1450837A4/fr
Priority to JP2003519439A priority patent/JP2005509597A/ja
Priority to CA002456762A priority patent/CA2456762A1/fr
Priority to MXPA04001187A priority patent/MXPA04001187A/es
Priority to AU2002324625A priority patent/AU2002324625B2/en
Publication of WO2003014309A2 publication Critical patent/WO2003014309A2/fr
Publication of WO2003014309A3 publication Critical patent/WO2003014309A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à des méthodes thérapeutiques de troubles médicaux caractérisées par des niveaux élevés ou l'expression anormale de IL-1 par administration d'un antagoniste de IL-1, notamment un récepteur soluble IL-1 de type II et/ou un IL-1RacP.
PCT/US2002/024948 2001-08-07 2002-08-07 Recepteurs de l'interleukine-1 dans le traitement de maladies WO2003014309A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP02759279A EP1450837A4 (fr) 2001-08-07 2002-08-07 Recepteurs de l'interleukine-1 dans le traitement de maladies
JP2003519439A JP2005509597A (ja) 2001-08-07 2002-08-07 疾患の治療におけるインターロイキン−１受容体
CA002456762A CA2456762A1 (fr) 2001-08-07 2002-08-07 Recepteurs de l'interleukine-1 dans le traitement de maladies
MXPA04001187A MXPA04001187A (es) 2001-08-07 2002-08-07 Receptores de interleucina-1 en el tratamiento de enfermedades.
AU2002324625A AU2002324625B2 (en) 2001-08-07 2002-08-07 Interleukin-1 receptors in the treatment of diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31078901P 2001-08-07 2001-08-07
US60/310,789 2001-08-07

Publications (2)

Publication Number Publication Date
WO2003014309A2 WO2003014309A2 (fr) 2003-02-20
WO2003014309A3 true WO2003014309A3 (fr) 2004-06-24

Family

ID=23204113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/024948 WO2003014309A2 (fr) 2001-08-07 2002-08-07 Recepteurs de l'interleukine-1 dans le traitement de maladies

Country Status (8)

Country Link
US (1) US20030049255A1 (fr)
EP (1) EP1450837A4 (fr)
JP (1) JP2005509597A (fr)
AU (1) AU2002324625B2 (fr)
CA (1) CA2456762A1 (fr)
MX (1) MXPA04001187A (fr)
PL (1) PL374118A1 (fr)
WO (1) WO2003014309A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10995144B2 (en) 2011-01-19 2021-05-04 Cantargia Ab Methods of detecting a solid tumor with anti-IL1RAP antibodies

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7771719B1 (en) * 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
IL138930A0 (en) * 1998-05-15 2001-11-25 Genentech Inc Il-17 homologies polypeptides and therapeutic uses thereof
US20040043397A1 (en) * 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20030203451A1 (en) * 2000-08-24 2003-10-30 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20090035261A1 (en) * 2000-03-21 2009-02-05 Jian Chen IL-17 homologous polypeptides and therapeutic uses thereof
US7718397B2 (en) * 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
US20030180255A1 (en) * 2000-08-24 2003-09-25 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20030096969A1 (en) * 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20070160576A1 (en) * 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
DK2784084T4 (da) * 2003-07-08 2024-01-08 Novartis Pharma Ag Antagonist-antistoffer mod IL-17A/F heterologe polypeptider
WO2005049056A2 (fr) * 2003-11-14 2005-06-02 Ucl Biomedica Plc Modulateur immunitaire
EP1983000B1 (fr) 2003-11-21 2015-09-02 UCB Biopharma SPRL Procédé pour le traitement de la sclérose en plaque par l'inhibition d'activité IL-17
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
JP5064212B2 (ja) * 2004-05-05 2012-10-31 ヴァロリザーシヨン−ルシェルシュ，ソシエテ・アン・コマンディット インターロイキン−１受容体アンタゴニスト、組成物、及び治療方法
AU2006230419A1 (en) * 2005-03-31 2006-10-05 Targeted Genetics Corporation Methods for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
JP2008542685A (ja) * 2005-05-05 2008-11-27 ヴァロリザーシヨン・アッシュエスジ，ソシエテ・アン・コマンディット サイトカイン受容体修飾因子及びその使用
US8642543B2 (en) * 2005-09-07 2014-02-04 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
EP3332807B1 (fr) 2005-10-26 2023-02-22 Novartis AG Utilisation d' anticorps anti il-1beta
US7504106B2 (en) * 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
JP2009183176A (ja) * 2008-02-05 2009-08-20 Univ Of Tokyo Ｉｌ−１タイプｉｉレセプター遺伝子の欠損変異体マウス
MX2010012090A (es) * 2008-05-05 2011-04-11 Novimmune Sa Anticuerpos anti-il 17 a/il-17f de reactividad cruzada y metodos de uso de los mismos.
KR101811886B1 (ko) 2009-05-05 2017-12-22 노비뮨 에스 에이 항―ｉｌ―17ｆ 항체 및 이의 사용 방법
GB2472856B (en) * 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
CA2825986C (fr) 2010-06-18 2019-10-29 Xbiotech Inc. Traitement de l'arthrite
US9724409B2 (en) * 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CA2894219C (fr) 2012-12-10 2020-08-11 Vib Vzw Nouveaux inhibiteurs de l'interleukine-33
CN108026172B (zh) 2015-06-26 2022-04-29 赛诺菲生物技术公司 单克隆抗il-1racp抗体
EP3241845A1 (fr) 2016-05-06 2017-11-08 MAB Discovery GmbH Anticorps anti-il-1r3 humanisés
EP3401332A1 (fr) 2017-05-08 2018-11-14 MAB Discovery GmbH Anticorps anti-il-1r3 destinés à être utilisés dans des conditions inflammatoires
CN110997725B (zh) 2017-06-12 2024-08-09 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
US11633425B2 (en) 2021-05-13 2023-04-25 Ahava—Dead Sea Laboratories Ltd. Anti-glycation compositions
CN120225564A (zh) 2022-09-21 2025-06-27 赛诺菲生物技术公司 人源化抗il-1r3抗体及其使用方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5488032A (en) * 1987-11-25 1996-01-30 Immunex Corporation Method of using soluble human interleukin-1 receptors to suppress inflammation
WO1996023067A1 (fr) * 1995-01-23 1996-08-01 F.Hoffmann-La Roche Ag Proteine accessoire humaine du recepteur de l'interleukine-1
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5965583A (en) * 1997-04-24 1999-10-12 Ortho-Mcneil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory disease
US6136810A (en) * 1995-11-21 2000-10-24 Yamanouchi Pharmaceutical Co., Ltd. Pyrido[2,3-D]pyrimidine derivatives and pharmaceutical compositions thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350683A (en) * 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
WO1991018982A1 (fr) * 1990-06-05 1991-12-12 Immunex Corporation Recepteurs de l'interleukine-1 de type ii
NZ251820A (en) * 1992-03-30 1996-07-26 Immunex Corp Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
US20010053764A1 (en) * 2000-05-12 2001-12-20 Sims John E. Interleukin-1 inhibitors in the treatment of diseases
WO2002064630A2 (fr) * 2000-10-31 2002-08-22 Immunex Corporation Proteine accessoire de recepteur de l'il-1

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5488032A (en) * 1987-11-25 1996-01-30 Immunex Corporation Method of using soluble human interleukin-1 receptors to suppress inflammation
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
WO1996023067A1 (fr) * 1995-01-23 1996-08-01 F.Hoffmann-La Roche Ag Proteine accessoire humaine du recepteur de l'interleukine-1
US6136810A (en) * 1995-11-21 2000-10-24 Yamanouchi Pharmaceutical Co., Ltd. Pyrido[2,3-D]pyrimidine derivatives and pharmaceutical compositions thereof
US5965583A (en) * 1997-04-24 1999-10-12 Ortho-Mcneil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1450837A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10995144B2 (en) 2011-01-19 2021-05-04 Cantargia Ab Methods of detecting a solid tumor with anti-IL1RAP antibodies
US11773174B2 (en) 2011-01-19 2023-10-03 Cantargia Ab Anti-IL1RAP antibodies and their use for treating humans

Also Published As

Publication number Publication date
AU2002324625B2 (en) 2008-05-08
US20030049255A1 (en) 2003-03-13
EP1450837A2 (fr) 2004-09-01
CA2456762A1 (fr) 2003-02-20
MXPA04001187A (es) 2004-07-08
WO2003014309A2 (fr) 2003-02-20
PL374118A1 (en) 2005-10-03
JP2005509597A (ja) 2005-04-14
EP1450837A4 (fr) 2006-01-04

Similar Documents

Publication Publication Date Title
WO2003014309A3 (fr) Recepteurs de l'interleukine-1 dans le traitement de maladies
WO2001087328A3 (fr) Inhibiteurs d"interleukine 1 dans le traitement de maladies
WO2002032374A3 (fr) Methodes de traitement de troubles induits par l'il-18
WO2000064441A3 (fr) Medicament
EP1485381B8 (fr) Azolylaminoazines en tant qu'inhibiteurs de proteines kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
WO2004071529A3 (fr) Utilisations d'anticorps contre le recepteur de facteur de croissance insulinoide i
WO2005028475A3 (fr) Compositions utiles pour inhiber des proteines kinases
WO2006047516A3 (fr) Composes et compositions servant d'inhibiteurs d'activite de recepteur cannabinoide de type 1
EP2322219A3 (fr) Utilisation des antagonistes IL-23 et IL-17 pour traiter la maladie inflammatoire oculaire auto-immune
BRPI0518228A (pt) inibidores de cinesina mitótica e métodos de uso destes
WO2005116088A3 (fr) Methodes et compositions pour traiter des maladies et des troubles associes a des cellules exprimant siglec-8
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
WO2004043341A3 (fr) Traitement pour choc hémorragique
EP2116245A3 (fr) combinaisons d'inhibiteurs de la kinase EGFR pour le traitement de désordres respiratoires et de l'appareil digestif
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2004093881A3 (fr) Utilisation du dipyridamole ou du mopidamole pour le traitement et la prevention de maladies thrombo-emboliques et de troubles induits par la formation excessive de thrombine et/ou par l'expression elevee des recepteurs de la thrombine
AU2003260436A1 (en) Pyrimidine compounds
EP1262197A3 (fr) Combinaison thérapeutique pour traiter les troubles du sommeil, y compris l'apnée du sommeil
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
WO2004056768A3 (fr) Utilisation de 2,5-diamidoindoles substitues pour le traitement de maladies urologiques
WO2000076500A3 (fr) Compound for use as a medicament for treatment of disorders involving bronchocontraction

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2456762

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 374118

Country of ref document: PL

Ref document number: PA/a/2004/001187

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003519439

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002324625

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002759279

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002759279

Country of ref document: EP